Clinical Trials in Maryland

Showing 19221-19240 of 23,284 trials

Interleukin-2 Plus Activated White Blood Cells in Treating Patients With Cancer That Has Not Responded to Chemotherapy or Radiation Therapy

NCT00019357

RATIONALE: Interleukin-2 may stimulate a person's white blood cells to kill tumor cells. Combining white blood cells, which have been activated by a vaccine, with interleukin-2 may kill more cancer cells. PURPOSE: Phase I trial to study the effectiveness of interleukin-2 plus activated white blood cells in treating patients with cancer that has not responded to chemotherapy or radiation therapy.

Unspecified Adult Solid Tumor, Protocol Specific

National Cancer Institute (NCI)Started Jun 1998

Bethesda, Maryland, United States

COMPLETEDPhase 117 miles

Gene Therapy and Biological Therapy in Treating Patients With Ovarian Epithelial Cancer

NCT00019136

RATIONALE: Interleukin-2 may stimulate a person's white blood cells to kill ovarian cancer cells. Interleukin-2 combined with white blood cells that are gene-modified to recognize and kill ovarian cancer cells may be an effective treatment for recurrent or residual ovarian cancer. PURPOSE: Phase I trial to study the effectiveness of interleukin-2 plus gene-modified white blood cells in treating patients who have advanced ovarian epithelial cancer.

Ovarian Cancer

National Cancer Institute (NCI)Started Feb 1997

Bethesda, Maryland, United States

COMPLETEDPhase 117 miles

UCN-01 and Fludarabine in Treating Patients With Recurrent or Refractory Lymphoma or Leukemia

NCT00019838

RATIONALE: Drugs used in chemotherapy work in different ways to stop cancer cells from dividing so they stop growing or die. Combining UCN-01 with chemotherapy may kill more tumor cells. PURPOSE: This phase I trial is studying the side effects and best dose of fludarabine when given with UCN-01 in treating patients with recurrent or refractory low-grade lymphoma or leukemia.

LeukemiaLymphoma

National Cancer Institute (NCI)Started Jul 1999

Bethesda, Maryland, United States • Bethesda, Maryland, United States

Interleukin-2 Plus Activated White Blood Cells in Treating Patients With Cancer That Has Not Responded to Chemotherapy or Radiation Therapy

Gene Therapy and Biological Therapy in Treating Patients With Ovarian Epithelial Cancer

UCN-01 and Fludarabine in Treating Patients With Recurrent or Refractory Lymphoma or Leukemia

Find Trials by Condition in Maryland

Vaccine Therapy With or Without Interleukin-2 in Treating Patients With Recurrent Metastatic Melanoma

Fluorescent Light Bronchoscopy Plus White Light Bronchoscopy for Early Detection of Lung Cancer

LMB-9 Immunotoxin in Treating Patients With Advanced Solid Tumors

Depsipeptide in Treating Patients With Solid Tumors

Paclitaxel and Hyperthermic Perfusion in Treating Patients With Lung Cancer or Lung Metastases That Cannot Be Removed By Surgery

Analysis of Genes Present in Cutaneous T-cell Lymphoma Cells

Vaccine Therapy Plus Sargramostim and Interleukin-2 Compared With Nilutamide Alone in Treating Patients With Prostate Cancer

Temozolomide and O6-benzylguanine in Treating Children With Solid Tumors

Genetic Study of Patients Previously Treated With Flavopiridol on Clinical Trial NCI-97-C-0171C

Possible New Therapy for Advanced Cancer

Examining the Effect of Acupuncture on Sleep Difficulties Related to Post Traumatic Stress Disorder

A Trial of an Oral Nutritional Supplement in Older Hospitalized Patients - NOURISH Study

A Patient-Centered Approach to Improve Screening for Side Effects of Second Generation Antipsychotics (SGAs)

ENSEAL® G2 Articulating Tissue Sealer in Laparoscopic Colectomy

An Open-Label, Multi-Center Clinical Trial of Eculizumab in Pediatric Patients With Atypical Hemolytic-Uremic Syndrome

Functional MRI in Lupus Nephritis

Comparison of Indacaterol 150 mcg Once Daily (o.d.) With Salmeterol/Fluticasone Propionate 50 mcg/500 mcg Twice Daily (b.i.d.)